INHIBIKASE THERAPEUTICS INC - COM (IKT)

CUSIP: 45719W106

Q1 2021 13F Holders as of 31 Mar 2021

Type / Class
Equity / COM
Total 13F shares
162,609
Share change
+27,559
Total reported value
$975,000
Price per share
$5.98
Number of holders
8
Value change
+$150,000
Number of buys
5
Number of sells
3

Quarterly Holders Quick Answers

What is CUSIP 45719W106?
CUSIP 45719W106 identifies IKT - INHIBIKASE THERAPEUTICS INC - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of INHIBIKASE THERAPEUTICS INC - COM (IKT) as of Q1 2021

As of 31 Mar 2021, INHIBIKASE THERAPEUTICS INC - COM (IKT) was held by 8 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 162,609 shares. The largest 8 holders included FMR LLC, ZEKE CAPITAL ADVISORS, LLC, CITADEL ADVISORS LLC, HRT FINANCIAL LP, MILLENNIUM MANAGEMENT LLC, ROYAL BANK OF CANADA, BlackRock Inc., and Tower Research Capital LLC (TRC). This page lists 8 institutional shareholders reporting positions in this security for the Q1 2021 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.